The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 5, 2012, Pages 599-613

  Martins, Renato G ^a   D'Amico, Thomas A ^b   Loo, Billy W ^c   Pinder Schenck, Mary ^d   Borghaei, Hossein ^e   Chaft, Jamie E ^f   Ganti, Apar Kishor P ^g   Kong, Feng Ming ^h   Kris, Mark G ^f   Lennes, Inga T ^h   Wood, Douglas E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g NEBRASKA MEDICAL CENTER   (United States)

^h UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; VINBLASTINE; VINCRISTINE;

BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPIC ECHOGRAPHY; EVIDENCE BASED MEDICINE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SURGERY; MEDIASTINOSCOPY; MEDIASTINUM LYMPH NODE; MEDIASTINUM METASTASIS; MORBIDITY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; THORAX SURGERY; TREATMENT RESPONSE; VIDEO ASSISTED THORACOSCOPIC SURGERY;

EID: 84861830553     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0062     Document Type: Review

References (67)

1. Ettinger DS, Akerly W, Bepler G, et al. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 2, 2012. Available at: NCCN.org. Accessed March 13, 2012.
2. Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol 2007;2:706-714. (Pubitemid 47357522)
3. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III nonsmall- cell lung cancer: a phase III randomized controlled trial. Lancet 2009;374:379-386.
4. Shah AA, Berry MF, Tzao C, et al. Induction chemoradiotherapy is not superior to induction chemotherapy alone in patients with stage IIIA(N2) non-small cell lung cancer: a systematic review and meta-analysis [abstract]. J Thorac Oncol 2011;6(Supp 2):S1578-1579. Abstract 4.290.
5. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000;18:2981-2989. (Pubitemid 30644122)
6. Cerfolio RJ, Bryant AS. Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer. Ann Thorac Surg 2008;86:362-367. (Pubitemid 351978042)
7. Hochstenbag MMH, Twijnstra A, Hofman P, et al. MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatement? Lung Cancer 2003;42:189-193. (Pubitemid 37268029)
8. Hwangbo B, Kim SK, Lee HS, et al. Application of endobronchial ultrasound-guided transbronchial needle aspiration following integrated PET/CT in mediastinal staging of potentially operable nonsmall cell lung cancer. Chest 2009;135:1280-1287.
9. Darling GE, Maziak DE, Inculet RI, et al. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. J Thorac Oncol 2011;6:1367-1372.
10. Farjah F, Flum DR, Varguese TK Jr, et al. Surgeon specialty and long-term survival after pulmonary resection for lung cancer. Ann Thorac Surg 2008;87:995-1004.
11. Burkes RL, Ginsberg RJ, Shepherd FA, et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto phase II trial. J Clin Oncol 1992;10:580-586.
12. Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993;55:1365-1373; discussion 1373-1374.
13. Elias AD, Skarin AT, Leong T, et al. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer 1997;17:147-161. (Pubitemid 27261499)
14. Pujol JL, Rossi JF, Le Chevalier T, et al. Pilot study of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancer. Eur J Cancer 1990;26:798-801. (Pubitemid 20328551)
15. Darwish S, Minotti V, Crino L, et al. Neoadjuvant cisplatin and etoposide for stage IIIA (clinical N2) non-small cell lung cancer. Am J Clin Oncol 1994;17:64-67. (Pubitemid 24062737)
16. Kris MG, Pisters KM, Ginsberg RJ, et al. Effectiveness and toxicity of preoperative therapy in stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (clinical N2). Lung Cancer 1995;12(Suppl 1):S47-57.
17. Betticher DC, Hsu Schmitz SF, Totsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003;21:1752-1759. (Pubitemid 46638588)
18. Martini N, Kris MG, Gralla RJ, et al. The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases (N2 M0). Ann Thorac Surg 1988;45:370-379. (Pubitemid 18097323)
19. Sugarbaker DJ, Herndon J, Kohman LJ, et al. Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. J Thorac Cardiovasc Surg 1995;109:473-483; discussion 483-485.
20. Burkes RL, Shepherd FA, Blackstein ME, et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial. Lung Cancer 2005;47:103-109. (Pubitemid 39643247)
21. Garrido P, Gonzalez-Larriba JL, Insa A, et al. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol 2007;25:4736-4742. (Pubitemid 350086475)
22. Weiden PL, Piantadosi S. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small cell lung cancer. A phase 2 study of the LCSG. Chest 1994;106(6 Suppl):344S-347S. (Pubitemid 24370972)
23. Taylor SG IV, Trybula M, Bonomi PD, et al. Simultaneous cisplatin fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III, non-small cell lung cancer. Ann Thorac Surg 1987;43:87-91. (Pubitemid 17004851)
24. D'Angelillo RM, Trodella L, Ciresa M, et al. Multimodality treatment of stage III non-small cell lung cancer: analysis of a phase II trial using preoperative cisplatin and gemcitabine with concurrent radiotherapy. J Thorac Oncol 2009;4:1517-1523.
25. Palazzi M, Cataldo I, Gramaglia A, et al. Preoperative concomitant cisplatin/VP16 and radiotherapy in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1993;27:621-625. (Pubitemid 23331130)
26. Choi NC, Carey RW, Daly W, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 1997;15:712-722. (Pubitemid 27074241)
27. Favaretto A, Paccagnella A, Tomio L, et al. Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. Feasibility, toxicity and long-term results of a phase II study. Eur J Cancer 1996;32A:2064-2069. (Pubitemid 26419454)
28. Eberhardt W, Wilke H, Stamatis G, et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998;16:622-634. (Pubitemid 28135609)
29. Strauss GM, Herndon JE, Sherman DD, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA nonsmall- cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992;10:1237-1244.
30. Eagan RT, Ruud C, Lee RE, et al. Pilot study of induction therapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M0 non-small cell lung cancer. Cancer Treat Rep 1987;71:895-900. (Pubitemid 17151363)
31. Faber LP, Kittle CF, Warren WH, et al. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg 1989;47:669-675; discussion 676-677.
32. Recine D, Rowland K, Reddy S, et al. Combined modality therapy for locally advanced non-small cell lung carcinoma. Cancer 1990;66:2270-2278.
33. Thomas M, Rübe C, Hoffnecht P, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small cell lung cancer. Lancet Oncol 2008;9:636-648.
34. Preoperative chemotherapy versus concurrent chemoradiotherapy in N2 positive IIIa non small cell lung cancer (NSCLC). ClinicalTrials. gov identifier: NCT00452803. Available at: www.clinicaltrials.gov/NCT00452803. Accessed November 21, 2011.
35. Chemotherapy with or without radiation therapy before surgery in treating patients with stage IIIA non-small cell lung cancer. Clinical Trials.gov identifier: NCT00030771. Available at: www.clinicaltrials. gov/NCT00030771. Accessed November 21, 2011.
36. van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007;99:442-450. (Pubitemid 47073567)
37. Mac Manus MP, Hicks RJ, Matthew JP, et al., High rate of detection of unsuspected distant metastases by PET in apparent stage III nonsmall- cell lung cancer: implications for radical radiation therapy. Intl J Radiat Oncol Biol Phys 2001;50:287-293. (Pubitemid 32472257)
38. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009;361:32-39.
39. Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non-small cell lung cancer. J Clin Oncol 2005;23:7763.
40. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181-2190.
41. Cerfolio R, A Bryant, B Ojha. Restaging patients with N2 (stage IIIA) nonsmall cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 2006;131:1229-1235. (Pubitemid 43792421)
42. Bauwens O, Dusart M, Pierard P, et al. Endobronchial ultrasound and value of PET for prediction of pathological results of mediastinal hot spots in lung cancer patients. Lung Cancer 2008;61:356-361.
43. Plat G, Pierard P, Haller A, et al. Endobronchial ultrasound and positron emission tomography positive mediastinal lymph nodes. Eur Respir J 2006;27:276-281. (Pubitemid 43180902)
44. Krupitskaya Y, Loo BW Jr. Post-operative radiation therapy (PORT) in completely resected non-small-cell lung cancer. Curr Treat Opt Oncol 2008;9:343-356.
45. Watanabe Y, Shimizu J, Tsubota M, et al. Mediastinal spread of metastatic lymph nodes in bronchogenic carcinoma. Mediastinal nodal metastases in lung cancer. Chest 1990;97:1059-1065. (Pubitemid 20166790)
46. Kotoulas CS, Foroulis CN, Kostikas K, et al. Involvement of lymphatic metastatic spread in non-small cell lung cancer accordingly to the primary cancer location. Lung Cancer 2004;44:183-191. (Pubitemid 38482051)
47. Cerfolio RJ, Bryant AS. Distribution and likelihood of lymph node metastasis based on the lobar location of nonsmall-cell lung cancer. Ann Thorac Surg 2006;81:1969-1973. (Pubitemid 43775576)
48. Kelsey CR, Light KL, Marks LB. Patterns of failure after resection of non-small-cell lung cancer: implications for postoperative radiation therapy volumes. Int J Radiat Oncol Biol Phys 2006;65:1097-1105.
49. Fowler WC, Langer CJ, Curran WJ, et al. Postoperative complications after combined neoadjuvant treatment of lung cancer. Ann Thorac Surg 1993;55:986-989. (Pubitemid 23130257)
50. Sonett JR, Suntharalingam M, Edelman MJ, et al. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. Ann Thorac Surg 2004;78:1200-1205. (Pubitemid 39303834)
51. Cerfolio RJ, Bryant AS, Jones VL, et al. Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for nonsmall cell lung cancer is safe and may provide increased survival. Eur J Cardiothorac Surg 2009;35:718-723.
52. Edelman MJ, Paulus R, Suntharalingam M, et al. RTOG 0229: a phase II trial of concurrent chemotherapy and full dose radiotherapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung [abstract]. J Thorac Oncol 2011;6:S375-376. Abstract O23.02.
53. Spoelstra FOB, Senan S, Le Péchoux C, et al. Variations in target volume definition for postoperative radiotherapy in stage III nonsmall- cell lung cancer: analysis of an international contouring study. Int J Radiat Oncol Biol Phys 2010;76:1106-1113.
54. Betticher DC, Hsu Schmitz SF, Tötsch M, et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006;94:1099-1106.
55. Stefani A, Alifano M, Bobbio A, et al. Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients. J Thorac Cardiovasc Surg 2010;140:356-363.
56. Kim AW, Liptay MJ, Bonomi P, et al. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg 2011;92:233-241; discussion 241-243.
57. Lee HY, Lee HJ, Kim YT, et al. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer. J Thorac Oncol 2010;5:497-503.
58. Mac Manus M, Hicks RJ. The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review. Int J Radiat Oncol Biol Phys 2008;72:1298-1306.
59. Dimitrakopoulou-Strauss A, Hoffman M, Bergner R, et al. Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-D-glucose- positron emission tomography: a feasibility study. Mol Imaging Biol 2007;9:308-317. (Pubitemid 47304781)
60. Kong FM, Frey KA, Quint LE, et al. A pilot study of [18F] fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol 2007;25:3116-3123. (Pubitemid 47218060)
61. Cerfolio RJ, Bryant AS, Winokur TS, et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:1903-1909; discussion 1909.
62. Ohtsuka T, Nomori H, Ebihara A, et al. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer. Ann Thorac Cardiovasc Surg 2006;12:89-94.
63. Eschmann SM, Friedel G, Paulsen F, et al. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007;34:463-471. (Pubitemid 46426996)
64. Rebollo-Aguirre AC, Ramos-Font C, Villegas Portero R, et al. Is FDGPET suitable for evaluating neoadjuvant therapy in non-small cell lung cancer? Evidence with systematic review of the literature. J Surg Oncol 2010;101:486-494.
65. Gaissert HA, Keum DY, Wright CD, et al. Operative risk of pneumonectomy-Influence of preoperative induction therapy. J Thorac Cardiovasc Surg 2009;138:289-294.
66. Mansour Z, Kochetkova EA, Ducrocq E, et al. Induction chemotherapy does not increase the operative risk of pneumonectomy. Eur J Cardiothorac Surg 2007;31:181-185. (Pubitemid 46150064)
67. Weder W, Collaud S, Eberhardt WEE, et al. Pneumectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. J Thorac Cardiovasc Surg 2010;139:1424-1430.